7/28/2019 Philippines: 1 Pager Country Profile

1/1

164|world malaria report 2012

Philippines Western Pacifc RegionPhase: Control. Impact: >75% decrease in case incidence 20002011.

I. Epidemiological profle

Population (UN Population Division) 2011 %

High transmission (1 case per 1000 population)Low transmission (0-1 cases per 1000 population)Malaria-ree (0 cases)Total

6 800 00068 900 00019 200 00094 900 000

77320

Parasites and vectors

Major plasmodium species: P. alciparum (75%), P. vivax(25%)Major anopheles species: An. favirostris, maculatus, balabacensis, Litoralis

Intervention WHO-recommended policies/strategiesYes/No

Yearadopted

ITN/LLIN ITNs/LLINs distributed ree o chargeITNs/LLINs distributed to all age groups

YesYes

20062000

IRS IRS is recommendedDDT is used or IRS YesNo

IPT IPT used to prevent malaria during pregnancy N/A

Casemanagement

Patients o all ages should receive diagnostic testRDTs used at community levelACT is ree or all ages in public sectorPre-reerral treatment with recommended medicinesOral artemisinin-based monotherapies are not registered

YesYesYesYesNo

2004200220032009

Antimalaria policy MedicineYear

adopted

First-line treatment o unconfrmed malariaFirst-line treatment oP. alciparumFor treatment ailure o P. alciparum

Treatment o severe malariaTreatment oP. vivax

ALAL+PQQN+T

QN+TCQ+PQ(14d)

200920092002

20022002

Therapeutic ecacity tests (therapeutic or parasitological ailure, %)

Medicine Year No. of studies Min Median Max Fol low-up

AL 2006-2009 4 0 0 4 28 days

III. Financing

PhilippineSea

Viet

Nam

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011

Government* Global Fund World Bank USAID/PMI WHO/UNICEF AUSAID

Contribution

(US$m)

* Expenditure: costs for sub-national level, health systems, human resources, etc not included.

40

35

30

25

2015

10

5

0

II. Intervention policies and strategies

Insecticides & spray materials

ITNs

Diagnostics

Antimalarial medicines

Monitoring and evaluation

Human resources & technical assistance

Management and other costs

IV. Coverage

Source: NMLCP, MIS 2009.

0

20

40

60

80

100

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011

Householdsor

population(%)

Population at high risk protected with IRSHouseholds with at least one ITNAll ages who slept under an ITNPopulation at r isk protected with ITNs

0

20

40

60

80

100

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011

Cas

es(%)

Suspected cases tested

P. fal ciparum cases potentially treated with ACT

Cases treated with any antimalarial

V. Impact

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011

Positivityrate(%)

ABER(%)

ABER (Micr. & RDT) RDT posivity rate Slide positivity rate

20

15

10

5

0

5

4

3

2

1

02000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011

Cases

60 000

50 000

40 000

30 000

20 000

10 000

0

Num

berofdeaths

600

500

400

300

200

100

0

Deaths Confirmed cases

Government and external fnancing Expenditure by intervention in 2011

Coverage o ITN and IRS Cases tested and ACT delivered: Programme data (public sector)

Malaria test positivity rate and ABER Microscopically confrmed cases and deaths

Distribution o confrmed malaria cases (per 1 000 population)

Insufficient data 0 00.1 1.0100.11.0 1050 50100 100